Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANCE: Adventitial Dexamethasone in Femoropopliteal Revascularization
NCT01983449Phase 4Completed
- Sponsor
- Mercator MedSystems
- Start
- Nov 2013
- Primary completion
- Dec 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dexamethasone in peripheral artery disease (PAD), sponsored by Mercator MedSystems. Primary endpoints: Major Adverse Limb Events or Peri-Operative Death at 30 days and Duplex Ultrasound Index Lesion Binary Restenosis at 12 months. Started Nov 2013; status: completed.
02
Drugs
dexamethasone
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT01983449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01983449.